Alnylam logo.jpg

Headquartered in Cambridge, MA, Alnylam is leading the translation of RNA interference (RNAi) into a new class of medicines for rare genetic, cardio-metabolic, hepatic infectious, and central nervous system (CNS)/ocular diseases. Based on Nobel Prize-winning science, RNAi therapeutics are a clinically validated approach for the treatment of severe and debilitating diseases. For more information visit www.alnylam.com.